Expert opinion on drug delivery最新文献

{"title":"A comprehensive review of the Maillard reaction in solid pharmaceutical dosage forms: a focus on lactose.","authors":"Jia Xiang, Shipeng Chen, Songwen Tan","doi":"10.1080/17425247.2026.2613921","DOIUrl":"10.1080/17425247.2026.2613921","url":null,"abstract":"<p><strong>Introduction: </strong>Solid dosage forms face the risk of the Maillard reaction during development and storage. This reaction occurs between reducing excipients and amino-group-containing drugs, potentially leading to discoloration, impurity formation, and degradation of active ingredients, significantly impacting product quality and excipient selection.</p><p><strong>Areas covered: </strong>Using lactose, a representative reducing excipient, as an example, this article systematically explores the mechanisms, influencing factors, control strategies, and potential applications of the Maillard reaction in solid dosage forms. It aims to provide theoretical support and practical guidance for formulation optimization, quality control, and innovative development of pharmaceutical preparations. Searches of Google Scholar and PubMed were undertaken to gather the literature included in this review.</p><p><strong>Expert opinion: </strong>The Maillard reaction between lactose and amino-group-containing drugs poses a significant quality risk, directly affecting the stability and safety of pharmaceutical preparations. In generic drug development, controlling this reaction is a critical step in achieving consistency with the reference listed drug (RLD). Instead of simply avoiding lactose, a proactive strategy should be adopted early in development. Through compatibility assessment, mechanistic studies, and comprehensive control measures, this challenge can be transformed into an opportunity for formulation optimization and innovation, thereby advancing the development of high-quality solid dosage forms.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"697-716"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of nanocarriers for the treatment of <i>Candida auris</i> infections.","authors":"Anna Jaromin, Robert Zarnowski, David R Andes, Ben J Boyd","doi":"10.1080/17425247.2025.2604680","DOIUrl":"10.1080/17425247.2025.2604680","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"601-604"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted delivery of therapeutics to the heart with calcium phosphate nanoparticles.","authors":"Camilla Fusacchia, Federica Mancini, Alessio Adamiano, Lorenzo Degli Esposti, Michele Iafisco","doi":"10.1080/17425247.2025.2599851","DOIUrl":"10.1080/17425247.2025.2599851","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with conventional therapies mainly providing symptomatic relief without targeting underlying molecular and cellular mechanisms. Additionally, limitations of systemic drug administration, including poor tissue targeting and low accumulation, highlight the need for innovative approaches.</p><p><strong>Areas covered: </strong>Nanomedicine offers promising strategies for CVDs. Among nanocarriers, calcium phosphate nanoparticles (CaP NPs) are particularly attractive due to their biocompatibility, biodegradability, pH-responsive behavior, and versatility for drug incorporation. This report summarizes recent advances, identified through a literature search using Web of Science, PubMed and Scopus, on the application of CaP NPs for CVD therapy. Although still in its infancy, emerging evidence, including studies in large animal models, suggests the CaP NPs can selectively target cardiac tissues and efficiently deliver diverse bioactive molecules.</p><p><strong>Expert opinion: </strong>CaP NPs represent a highly promising platform for cardiovascular therapy. Their safety and potential for noninvasive inhalation administration could enable precise, effective, and patient-friendly treatments. Future research, including comparative studies with other nanocarriers, will help to validate their therapeutic potential. Continued development of CaP NP-based strategies may transform CVD management by enabling molecular-level interventions that improve clinical outcomes, reduce systemic side effects, and allow rapid and convenient dosing.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"611-619"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opsonized bilirubin nanomedicine targeting and repolarizing macrophage for acute lung injury treatment.","authors":"Yinhao Lin, Yanxian Hou, Baiqun Duan, Yingtao Li, Yongshuai Kang, Linying Wang, Jie Ding, Yitianhe Xu, Miyun Hu, Wenjing Cai, Fangfang Lv, Longfa Kou, Ruijie Chen, Hailin Zhang","doi":"10.1080/17425247.2025.2610393","DOIUrl":"10.1080/17425247.2025.2610393","url":null,"abstract":"<p><strong>Background: </strong>Acute lung injury (ALI) is a pathological condition characterized by diffuse lung injury. Excessive macrophage polarization to the M1 type in lung tissue plays a crucial role in the incidence and aggravation of ALI.</p><p><strong>Research design and methods: </strong>Bilirubin (BR) has been applied as a therapeutic agent in various diseases due to its ability to regulate macrophage polarization. Based on the inherent engulfing of M1 macrophages toward xenobiotic nanomedicines, an inhalable BR nanomedicine was developed for the treatment of ALI. The BR nanoparticles (BRn) were first prepared using a one-step nanoprecipitation method, followed by surface modification with immunoglobulin G (IgG) at a 20% weight ratio to prepare BRn@IgG.</p><p><strong>Results: </strong>Both nanoparticles exhibited excellent stability and enhanced antioxidative properties in aqueous phases. To gain the initiative, the IgG-modified nanoparticles could smartly bind to M1 macrophages, resulting in greatly improved BR delivery efficiency to macrophages and thus enhancing antioxidative, anti-inflammatory, and polarization-regulating effects compared to naked BRn. BRn@IgG evaded mechanical clearance from lung tissue and demonstrated prolonged retention in the pulmonary environment, thereby attaining the most potent therapeutic effect among all formulations in this study.</p><p><strong>Conclusion: </strong>BRn@IgG could be considered a novel and effective therapeutic agent for the ALI treatment.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"745-759"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of iron oxide nanoparticles in liver drug delivery: insights into biodegradation and toxicity at cellular, tissue, and organ levels.","authors":"Anna F Sheptulina, Ekaterina O Moiseeva, Sergei V German, Diana L Valeeva, Maria A Blindman, Dmitry A Gorin","doi":"10.1080/17425247.2026.2613932","DOIUrl":"10.1080/17425247.2026.2613932","url":null,"abstract":"<p><strong>Introduction: </strong>Due to its unique anatomical and physiological properties, the liver is known to capture the prevailing amount of intravenously administered nanoparticles. However, selectively delivering them to hepatocytes, the primary cells affected in most liver diseases, remains challenging, as nanoparticles are predominantly internalized by Kupffer cells, triggering inflammatory responses and fibrosis. Iron oxide nanoparticles can be engineered for active hepatocyte targeting via surface ligand modification, taking into account the nanoparticle size.</p><p><strong>Areas covered: </strong>This review covers the interactions between iron oxide nanoparticles, Kupffer cells, hepatic stellate cells, and hepatocytes. Iron oxide nanoparticles may induce hepatocellular toxicity through mechanisms such as oxidative stress, lysosomal and mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy impairment. Furthermore, iron metabolism and some proteins involved in the regulation of iron homeostasis are also addressed. The role of the Z-potential, size, and surface modification of nanoparticles were analyzed from the point of view of their uptake by liver cells. The corona and margination effects for iron oxide nanoparticles were considered.</p><p><strong>Expert opinion: </strong>Iron oxide nanoparticles hold significant potential for targeted hepatocyte delivery, provided that their physicochemical properties are carefully optimized to minimize off-target uptake by Kupffer cells and reduce hepatotoxicity. A comprehensive understanding of nanoparticle - cell interactions, iron homeostasis, and the impact of surface engineering is essential for the rational design of safer and more effective nanocarriers. Future progress will depend on balancing hepatocyte-specific targeting with biocompatibility, enabling the translational application of iron oxide nanoparticles in the diagnosis and treatment of liver diseases.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"717-743"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How might intraluminal drug-delivery strategies be improved to enhance arteriovenous fistula maturation and patency?","authors":"Justin George, Ajit Rao, Alan Dardik","doi":"10.1080/17425247.2025.2588377","DOIUrl":"10.1080/17425247.2025.2588377","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"597-600"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing deferoxamine delivery through the skin for pressure ulcers.","authors":"Katharina S Berryman, Maria Gracia Mora Pinos, Amy Skarsfeldt, Lulejeta Latifi, Pedro Mora Pinos, Kellen Chen, Geoffrey C Gurtner","doi":"10.1080/17425247.2025.2609683","DOIUrl":"10.1080/17425247.2025.2609683","url":null,"abstract":"<p><strong>Introduction: </strong>Deferoxamine (DFO) is an iron-chelator, approved for systemic treatment of iron overload. New research finds local applications to mechanistically correct ischemia-driven hypoxia that underlies chronic wound pathology resulting in therapeutic angiogenesis. Development of composite hydrogels and hybrid biomaterials that combine natural and synthetic polymers for enhanced mechanical integrity, antimicrobial function, and controlled drug release confirms that the field is moving toward multifunctional, bio-responsive wound therapies. Incorporating deferoxamine via reverse-micelle technology in a Deferoxamine Intradermal Delivery Patch (DIDP) advances this field by integrating a clinically approved, mechanistically targeted drug within a biocompatible matrix supported by preclinical safety and translational feasibility.</p><p><strong>Areas covered: </strong>We review transdermal application of deferoxamine and current biomaterials that enable dermal penetration of hydrophilic drugs. We discuss the first-ever in-human clinical application of DIDP and scarcity of clinical trials. Furthermore, we outline necessary steps for broad implementation of DIDP and explore potential future applications, including combination therapies.</p><p><strong>Expert opinion: </strong>Deferoxamine provides a remarkable ability to induce therapeutic angiogenesis despite diabetes or increased age, and this therapy could be utilized for other diseases that impair wound healing such as autonomic skin dysfunction following complete spinal cord injury. We identify efforts to increase the long-term safety profiles and advocate for large-scale randomized clinical trials.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"621-630"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncofetal chondroitin sulfate in cancer therapy: a promising target for anti-tumor drug delivery?","authors":"Elena Ethel Vidal-Calvo, Ali Salanti","doi":"10.1080/17425247.2025.2606747","DOIUrl":"10.1080/17425247.2025.2606747","url":null,"abstract":"","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"605-610"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-articular targeted delivery of nanomaterials for the treatment of osteoarthritis: focusing on cell signaling pathway mechanisms.","authors":"Bo Gu, Jingjing Qi, Xin Li, Shuya Wang, Yuanqiang Ma, Jiantao Zhang, Tianwen Ma","doi":"10.1080/17425247.2025.2600610","DOIUrl":"10.1080/17425247.2025.2600610","url":null,"abstract":"<p><strong>Introduction: </strong>This review summarizes the application of nanomaterial-mediated intra-articular targeted drug delivery systems in the treatment of osteoarthritis (OA) and their regulatory mechanisms on key cellular signaling pathways. Studies have shown that novel nanocarriers can effectively load, deliver, and controllably release therapeutic agents, significantly enhancing drug bioavailability and reducing systemic toxicity. By precisely modulating signaling pathways, nanomaterials (NM) can effectively suppress inflammatory responses, alleviate oxidative stress, promote chondrocyte anabolism, delay extracellular matrix degradation, and regulate programmed cell death. This study highlights the potential of NM as a multi-target, synergistic therapeutic strategy for OA intervention, providing a theoretical and experimental basis for the development of next-generation precision therapies for OA.</p><p><strong>Areas covered: </strong>This paper reviews the research progress of nano-drug delivery technology in the treatment of joint diseases, focusing on the potential mechanisms of targeted drug delivery and retention, promoting regeneration and repair, and realizing anti-inflammatory and antioxidant effects. We identified relevant literature through PubMed and Web of Science, focusing on studies published over the past five years.</p><p><strong>Expert opinion: </strong>Nanomaterials for osteoarthritis treatment are evolving from passive drug carriers to intelligently responsive, targeted multifunctional systems capable of personalized, proactive, and regenerative therapy, overcoming current limitations in toxicity and delivery precision.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"643-659"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing antiviral therapy: harnessing nanotechnology to unlock the power of phytoconstituents.","authors":"Zainab Choonia, Kailash Patil, Trinette Fernandes, Shridhar Narayanan, Sujata Sawarkar, Abdelwahab Omri","doi":"10.1080/17425247.2025.2609682","DOIUrl":"10.1080/17425247.2025.2609682","url":null,"abstract":"<p><strong>Introduction: </strong>Viral diseases such as influenza, severe acute respiratory syndrome (SARS) caused due to coronaviruses (CoVs), Ebola, and acquired immunodeficiency syndrome (AIDS) caused due to human immunodeficiency virus (HIV) are still some of the major global causes of morbidity and mortality. Traditional antiviral therapies face limitations because of resistance development and toxicity. As a result, plant-derived medicines are gaining more attention for their therapeutic potential, owing to their lower toxicity and reduced likelihood of resistance development.</p><p><strong>Areas covered: </strong>This review critically examines the antiviral properties of phytoconstituents like coumarins, steroids, and polysaccharides against various viruses. It discusses their integration with nanotechnology delivery systems to overcome bioavailability issues and highlights the need for translational studies to corroborate in vitro results.</p><p><strong>Expert opinion: </strong>The convergence of phytotherapy and nanotechnology represents a promising frontier in antiviral drug development. While significant progress has been made in identifying active phytochemicals and formulating them with nanocarriers, more <i>in-vivo</i> data, clinical research, standardization efforts, and regulatory clarity are needed. This review may serve as a foundational resource for researchers aiming to develop innovative antiviral therapies based on natural compounds and nanotechnology-based delivery systems.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"661-679"},"PeriodicalIF":5.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}